| Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice. | |
| | |
MedLine Citation:
|
PMID: 20655898 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Recent evidence suggests that the forkhead transcription factor Foxo1 plays an important role in the regulation of glucose and triglyceride metabolism at the gene transcription level for glucose-6 phosphatase (G6Pase), phosphoenolpyruvate carboxykinase (PEPCK), and apolipoprotein C-III (apoC-III). Here, we report on the pharmacological effects of the novel Foxo1 inhibitor AS1708727, which we identified by compound screening. Chronic treatment of diabetic db/db mice with AS1708727 for four days significantly reduced blood glucose and triglyceride levels with decrease of gene expression levels of hepatic G6Pase, PEPCK, and apoC-III. No reports have yet examined the influence of Foxo1 inhibitors on these pharmacological effects. In this study, we newly identified a Foxo1 inhibitor compound capable of exerting both an anti-hypertriglyceridemic and anti-hyperglycemic effect. These effects were dependent on maintaining a stable blood concentration of AS1708727 and achieving a high rate of compound transition to the liver. We also investigated the action mechanism of AS1708727 on gluconeogenesis in vitro and in vivo. The compound inhibited gene expression of key gluconeogenic molecules and suppressed gluconeogenesis in Fao hepatocyte cells in vitro. Further, in the pyruvate challenge study using db/db mice in vivo, AS1708727 suppressed increases in blood glucose level by inhibiting gluconeogenic gene expression. These results indicate that the novel Foxo1 inhibitor AS1708727 may exert anti-diabetic and anti-hypertriglyceridemic effects by improving blood glucose and triglyceride metabolism at the gene expression level, and may represent a new class of drugs useful for treating type 2 diabetes mellitus and hypertriglyceridemia. |
| | |
Authors:
|
Hirotsugu Tanaka; Takeyuki Nagashima; Akiyoshi Shimaya; Yasuharu Urano; Teruhiko Shimokawa; Masayuki Shibasaki |
Related Documents
:
|
12369708 - Brain-derived neurotrophic factor regulates energy expenditure through the central nerv... 12540618 - Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in ... 17719208 - Topical application of laminin-332 to diabetic mouse wounds. 16828268 - Feasibility of microneedles for percutaneous absorption of insulin. 19950068 - Morphological and morphometric studies of the aorta, pulmonary trunk, and heart of stre... 19464008 - Leukocyte telomere shortening in elderly type2dm patients with previous myocardial infa... |
Publication Detail:
|
Type: Journal Article Date: 2010-07-23 |
Journal Detail:
|
Title: European journal of pharmacology Volume: 645 ISSN: 1879-0712 ISO Abbreviation: Eur. J. Pharmacol. Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-08-30 Completed Date: 2011-01-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 1254354 Medline TA: Eur J Pharmacol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 185-91 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier B.V. All rights reserved. |
Affiliation:
|
Pharmacology Research Labs, Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tuskuba, Ibaraki 305-8585, Japan. hirotsugu.tanaka@jp.astellas.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetanilides
/
pharmacokinetics* Animals Apolipoprotein C-III / metabolism Blood Glucose / metabolism* Cells, Cultured Diabetes Mellitus, Type 2 / metabolism* Forkhead Transcription Factors / antagonists & inhibitors* Gluconeogenesis Glucose-6-Phosphatase / metabolism Hepatocytes / drug effects, metabolism Hypertriglyceridemia / metabolism Hypoglycemic Agents / pharmacology* Hypolipidemic Agents / pharmacology* Isoquinolines / pharmacokinetics* Male Mice Mice, Inbred C57BL Phosphoenolpyruvate Carboxykinase (GTP) / metabolism Triglycerides / blood* |
| Chemical | |
Reg. No./Substance:
|
0/2-cyclopentyl-N-(2,4-dichloro-3-((isoquinolin-5-yloxy)methyl)phenyl)-N-methylacetamide; 0/Acetanilides; 0/Apolipoprotein C-III; 0/Blood Glucose; 0/Forkhead Transcription Factors; 0/Foxo1 protein, mouse; 0/Hypoglycemic Agents; 0/Hypolipidemic Agents; 0/Isoquinolines; 0/Triglycerides; EC 3.1.3.9/Glucose-6-Phosphatase; EC 4.1.1.32/Phosphoenolpyruvate Carboxykinase (GTP) |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Major involvement of connexin 43 in seminiferous epithelial junction dynamics and male fertility.
Next Document: Hepatocyte growth factor protects human embryonic stem cell derived-neural progenitors from hydrogen...